NexBio, Inc. Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
11/9/2009 10:59:43 AM
More...
|
NexBio, Inc. Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
11/6/2009 10:04:43 AM
More...
|
NexBio, Inc. Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009
9/14/2009 11:00:00 AM
More...
|
NexBio, Inc. New Flu Drug May Resist Mutations, Researchers Say
9/14/2009 7:54:30 AM
More...
|
NexBio, Inc. Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
8/26/2009 7:59:11 AM
More...
|
NexBio, Inc. Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
4/15/2009 10:49:28 AM
More...
|
NexBio, Inc. Receives Phase II SBIR Grant to Add New Genomic and Proteomic Content
4/14/2009 9:21:12 AM
More...
|
NexBio, Inc. Completes First-in-Man Clinical Trial With DAS181 (Fludase(R)) and Strengthens Clinical Leadership
1/20/2009 8:26:51 AM
More...
|
NexBio, Inc. Awarded 'SCIENTIFIC AMERICAN 50' For Its Quest For The Ultimate Influenza Medicine
11/8/2005 11:29:59 AM
More...
|
NexBio, Inc. Receives A $6 Million National Institutes of Health (NIH) SBIR Grant For The Clinical Development Of A Novel Influenza Medicine
10/19/2005 5:09:06 PM
More...
|